Dr. Reddy's Laboratories · NSE: DRREDDY · BSE: 500124

Q1 FY22 results · Apr–Jun 2021

Dr. Reddy's Laboratories reported revenue from operations of ₹4,945.10 crore (up 11.7% from Q1 FY21) and net profit of ₹380.40 crore (down 36.0% from Q1 FY21) for Q1 FY22 (Apr–Jun 2021), on a consolidated basis.

Consolidated · ₹ crore
ItemQ1 FY22Q1 FY21YoYQ4 FY21QoQ
Revenue from operations4,945.104,426.50+11.7%4,768.20+3.7%
Other income107.9087.10+23.9%82.60+30.6%
Total income5,053.004,513.60+12.0%4,850.80+4.2%
Profit before share of associates & JVs and tax539.20892.80−39.6%797.30−32.4%
Share of profit/(loss) of associates & JVs16.607.7017.90
Net profit for the period380.40594.60−36.0%557.30−31.7%
EPS, basic (₹)22.9535.87−36.0%33.61−31.7%
Net margin (%)7.713.411.7

This company reports a share of profit/(loss) from associates and joint ventures. BSE’s filing format records that share after tax, so it is shown on its own line. The company’s own statement may add it before its “profit before tax” line.

Standalone · ₹ crore
ItemQ1 FY22Q1 FY21YoYQ4 FY21QoQ
Revenue from operations3,433.503,244.40+5.8%3,350.70+2.5%
Other income186.20644.70−71.1%81.60+128.2%
Total income3,619.703,889.10−6.9%3,432.30+5.5%
Profit before tax544.501,361.70−60.0%456.90+19.2%
Net profit for the period413.40950.20−56.5%311.50+32.7%
EPS, basic (₹)24.9457.31−56.5%18.78+32.8%
Net margin (%)12.029.39.3
Consolidated
Filed with BSE
27 Jul 2021, 12:41 IST
Board meeting
27 Jul 2021
Period
01 Apr 2021 to 30 Jun 2021
Review status
Unaudited
Source
XBRL filing on BSE
Standalone
Filed with BSE
27 Jul 2021, 12:41 IST
Board meeting
27 Jul 2021
Period
01 Apr 2021 to 30 Jun 2021
Review status
Unaudited
Source
XBRL filing on BSE